Eagle Pharmaceuticals/EGRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Ticker

EGRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Graves

Employees

134

Headquarters

Woodcliff lake, United States

EGRX Metrics

BasicAdvanced
$45M
Market cap
3.81
P/E ratio
$0.91
EPS
0.47
Beta
-
Dividend rate
$45M
0.46562
$23.52
$3.21
151K
2.161
1.671
24.558
27.85
3.064
3.55%
3.04%
4.88%
4.04%
3.809
0.175
0.18
0.452
-5.38%
-48.44%
17.36%
39.16%

What the Analysts think about EGRX

Analyst Ratings

Majority rating from 2 analysts.
Buy

EGRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
7.89% profit margin
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
$65M
-2.56%
Net income
$5.1M
-10.53%
Profit margin
7.89%
-8.15%

EGRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.00%
QuarterlyAnnual
Q3 22
Q4 22
Q1 23
Q2 23
Actual
$1.12
$1.10
$1.26
-
Expected
$0.91
$0.83
$1.05
$1.05
Surprise
23.53%
32.53%
20.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals (EGRX) has a market cap of $45M as of June 20, 2024.

What is the P/E ratio for Eagle Pharmaceuticals stock?

The price to earnings (P/E) ratio for Eagle Pharmaceuticals (EGRX) stock is 3.81 as of June 20, 2024.

Does Eagle Pharmaceuticals stock pay dividends?

No, Eagle Pharmaceuticals (EGRX) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Eagle Pharmaceuticals dividend payment date?

Eagle Pharmaceuticals (EGRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Eagle Pharmaceuticals?

Eagle Pharmaceuticals (EGRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Eagle Pharmaceuticals stock price target?

The target price for Eagle Pharmaceuticals (EGRX) stock is $17, which is NaN% below the current price of $. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Eagle Pharmaceuticals stock

Buy or sell Eagle Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing